{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:32:08Z","timestamp":1791037928047,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.blre.2020.100738","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T10:56:58Z","timestamp":1595242618000},"page":"100738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL"],"prefix":"10.1016","volume":"46","author":[{"given":"Akihiro","family":"Ohmoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Fuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2020.100738_bb0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.blre.2020.100738_bb0010","author":"NCCN Clinical Practice Guidelines in Oncology"},{"key":"10.1016\/j.blre.2020.100738_bb0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bjh.12573","article-title":"Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas","volume":"163","author":"Aalipour","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100738_bb0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0025","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2020.100738_bb0030","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0035","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0040","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","author":"R\u00e9cher","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2020.100738_bb0045","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0050","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0055","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0060","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.blre.2016.06.003","article-title":"Clinical approach to diffuse large B cell lymphoma","volume":"30","author":"Caimi","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2020.100738_bb0065","doi-asserted-by":"crossref","first-page":"448","DOI":"10.4143\/crt.2014.034","article-title":"Clinical significance of non-neutropenic fever in the management of diffuse large B-cell lymphoma patients treated with rituximab-CHOP: comparison with febrile neutropenia and risk factor analysis","volume":"47","author":"Park","year":"2015","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.blre.2020.100738_bb0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjh.12765","article-title":"Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study","volume":"165","author":"Wieringa","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100738_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-04495-x","article-title":"Infection is an independent predictor of death in diffuse large B cell lymphoma","volume":"7","author":"Dendle","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2020.100738_bb0080","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1080\/10428194.2018.1515940","article-title":"Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study","volume":"60","author":"Sharman","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2020.100738_bb0085","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3324\/haematol.2011.056531","article-title":"A Cancer and Leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype","volume":"97","author":"Wilson","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2020.100738_bb0090","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0095","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.13273","article-title":"Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group","volume":"169","author":"Purroy","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100738_bb0100","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2141.2006.06438.x","article-title":"Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study","volume":"136","author":"Garc\u00eda-Su\u00e1rez","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100738_bb0105","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0110","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0115","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0120","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD Study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0125","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3324\/haematol.13440","article-title":"R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study","volume":"93","author":"Mart\u00edn","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2020.100738_bb0130","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/cncr.20587","article-title":"Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)","volume":"101","author":"Crump","year":"2004","journal-title":"Cancer."},{"key":"10.1016\/j.blre.2020.100738_bb0135","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial","volume":"98","author":"Mounier","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2020.100738_bb0140","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100738_bb0145","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","article-title":"Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"31","author":"Ohmachi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0150","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100738_bb0155","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2017-08-802561","article-title":"A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL","volume":"131","author":"Sauter","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100738_bb0160","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100738_bb0165","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2020.100738_bb0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100738_bb0180","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.24499","article-title":"Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy","volume":"91","author":"Barreto","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100738_bb0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000334113","article-title":"The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim\/sulfamethoxazole: a single-center experience","volume":"127","author":"Hardak","year":"2012","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2020.100738_bb0190","article-title":"Prophylaxis and treatment of pneumocystis jiroveci pneumonia in lymphoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2020.100738_bb0195","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11899-013-0171-4","article-title":"Febrile neutropenia in hematologic malignancies","volume":"8","author":"Keng","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2020.100738_bb0200","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/10428194.2019.1666378","article-title":"Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody","volume":"61","author":"Sarlo","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2020.100738_bb0205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/cid\/ciy458","article-title":"Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine","volume":"68","author":"Fung","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2020.100738_bb0210","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.3109\/10428194.2015.1126589","article-title":"Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine","volume":"57","author":"Isono","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2020.100738_bb0215","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1038\/bcj.2015.86","article-title":"Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma","volume":"5","author":"Saito","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100738_bb0220","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0225","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2020.100738_bb0230","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.blre.2020.100738_bb0235","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2020.100738_bb0240","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00005792-199611000-00001","article-title":"X-linked agammaglobulinemia. A clinical and molecular analysis","volume":"75","author":"Ochs","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.blre.2020.100738_bb0245","article-title":"Immunomodulatory effect of ibrutinib: reducing the barrier against fungal infections","author":"Maffei","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2020.100738_bb0250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clml.2019.10.004","article-title":"Risk of infection associated with ibrutinib in patients with B-cell malignancies: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Ball","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2020.100738_bb0255","first-page":"4187","article-title":"Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001\u20132005 using the Japan Adult Leukemia Study Group AML201 protocols","volume":"26","author":"Kato","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.blre.2020.100738_bb0260","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.bbmt.2018.03.018","article-title":"De-escalation and discontinuation of empirical antibiotic treatment in a cohort of allogeneic hematopoietic stem cell transplantation recipients during the pre-engraftment period","volume":"24","author":"Gustinetti","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2020.100738_bb0265","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2015.03.018","article-title":"Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study","volume":"21","author":"Sun","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2020.100738_bb0270","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-3901-y","article-title":"A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005 - 2016","volume":"19","author":"Valentine","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2020.100738_bb0275","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","article-title":"ESMO guidelines working group. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications","volume":"21","author":"Crawford","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0280","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.bbmt.2018.05.017","article-title":"Comparative efficacy and safety of different antiviral agents for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"24","author":"Gagelmann","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2020.100738_bb0285","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab-related viral infections in lymphoma patients","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2020.100738_bb0290","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1080\/10428194.2016.1267352","article-title":"Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors","volume":"58","author":"Giridhar","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2020.100738_bb0295","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3892\/ol.2016.4683","article-title":"Disseminated herpes zoster infection initially presenting with abdominal pain in patients with lymphoma undergoing conventional chemotherapy: a report of three cases","volume":"12","author":"Okuma","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.blre.2020.100738_bb0300","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel - an update","volume":"57","author":"Cheson","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2020.100738_bb0305","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2020.100738_bb0310","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100738_bb0315","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/asheducation-2014.1.576","article-title":"Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy","volume":"2014","author":"Kusumoto","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2020.100738_bb0320","author":"NCCN Clinical Practice Guidelines in Oncology"},{"key":"10.1016\/j.blre.2020.100738_bb0325","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/10428194.2018.1499904","article-title":"The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome\/myeloproliferative neoplasm: a large population-based cohort study","volume":"60","author":"Ganzel","year":"2019","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:25:06Z","timestamp":1759436706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":65,"alternative-id":["S0268960X20300886"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100738","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100738"}}